Conquest of low survival gallbladder cancer

Handok HDB001A was approved IND for multi-national clinical phase2/3 for domestic approval

Major bio ventures are being verified for the combination of Keytruda

In the area of bile duct cancer, where survival rates are low and treatment options are scarce, new drug candidates from domestic pharmaceutical companies have been confirmed in clinical practice and are one step closer to commercialization.

 

HDB001A, a new drug candidate for gallbladder cancer that Handok is developing, has recently been approved by a multi-national Phase 2/3 clinical trial plan (IND) in Korea.

 

The company plans to compare and evaluate the effectiveness of Paclitaxel alone through the combination of HDB001A and platinum-based anticancer drug Paclitaxel.

 

Handok emerged as a dark horse in the area as HDB001A entered a late clinical trial, along with the acquisition of domestic permission for the new gallbladder cancer drug , which was introduced from U.S.

 

company Insight.

 

Major bioventures plan to confirm their effectiveness through the combination of new drug candidates and immunocancer drugs under development.

 

Genome & Company GEN-101, G Innovation GI-101, and SMT Bio SMT-NK are each undergoing clinical trials in combination with Keytruda.

 

Handok confirms the validity of Phase 2 clinical trial Handok is collaborating with Compass Therapeutics in the United States to develop a treatment for bile duct cancer.

 

HDB001A, which is being developed, is a new drug candidate for gall cancer developed by ABL Bio, a domestic company, and the domestic copyright is held by Handok and the global copyright is held by Compass.

 

HDB001A is known to simultaneously target DLL4 and VEGFA and play a role in the formation of new blood vessels in tumor-fine environments.

 

The company aims to obtain conditional approval from the Ministry of Food and Drug Safety through clinical results that will end next year.

 

Last month, SMT-NK was recognized by the Ministry of Food and Drug Safety and obtained approval for the use of drugs for clinical trials in patients with bile duct cancer.

 

G-I Innovation is undergoing clinical phase 1 in the United States to confirm the effectiveness of GI-101 and kitluda combination therapy.

 

It aims to secure indications for solid cancer that include bile duct cancer.

 

The company is confirming the possibility of commercialization through combination therapy with various immune anticancer drugs.

 

5-year survival rate of bile duct cancer 29%, Evaluation of lack of professional treatment options for bile duct cancer Bleduct cancer is one of the cancers that is difficult to diagnose early because there are no self-aware symptoms.

 

The 5-year survival rate for bile duct cancer is 29%, which is lower than lung cancer (34%) and liver cancer (37%).

 

As early diagnosis is difficult, treatment options are limited.

 

In advanced bile duct cancer, platinum-based chemotherapy has been used as a standard treatment for the past 10 years.

 

This is a first-generation anticancer drug, a cytotoxic anticancer drug that is used not only for bile duct cancer but also for lung cancer and colorectal cancer.

 

Side effects are also known to be high.

 

Secondary standard therapy includes FOLFOX, but it is also not a specialized treatment for bile duct cancer.

 

Recently, immunoanticancer agents have secured encouraging data and are attracting expectations.

 

The impinji developed by AZ was approved as the first treatment in the country in November last year.

 

However, targeted treatments for bile duct cancer are still insufficient.

 

It is noteworthy whether new drug candidates from domestic pharmaceutical companies can solve the unfulfilled demand of bile duct cancer patients.